Pharmacokinetics and Drug Metabolism in Canada: The Current Landscape

© 2019 by the authors; CC BY license

20-hydroxyeicosatetraenoic acid (20-HETE); Cytochrome P450s (CYPs); arachidonic acid (AA); kidney; ischemia/reperfusion (I/R) injury; liver; lung; brain; theophylline; theophylline metabolism; lung; microsomes; theophylline-7β-d-ribofuranoside; theonosine; glucosamine; nutraceutical; osteoarthritis; pharmacokinetics; polyphenols; veterinary medicine; UDP-glucuronosyltransferase; latency; microsomes; glucuronidation; regulation; doxorubicin; quercetin; pharmacokinetics; bioavailability; lymphatics transport; toxicity; augmented renal clearance; enhanced renal function; critically ill; Keywords: cytochromes P450; drug metabolism; mRNA; diet induced obesity; diabetes; oral absorption; physiologically-based pharmacokinetic modeling; food-effect; pH effect; formulation simulation; statins; loratadine; drug-transporters; MCT; monocarboxylate transporters; lactic acid; skeletal muscle cell; drug-induced muscle disorders; clinical pharmacokinetics; therapeutic drug monitoring; interstitial fluid; microneedles; arachidonic acid; CYP450 enzymes; Type II diabetes; cardiovascular disease; curcumin; tetrahydrocurcumin; calebin-A; UHPLC–MS/MS; pharmacokinetics; antioxidant; anti-inflammatory; anticancer; HDAC; HAT; hemophilia A; conventional factor VIII; dose metrics; obesity; population pharmacokinetics; antiretrovirals; transporters; P-glycoprotein; breast cancer resistance protein; multidrug resistance associated protein; gene regulation; protease inhibitor; Pregnane X Receptor; placenta; knockout mice; cyclophilin inhibitor; CRV431; P450; metabolism; species differences; lidocaine; pharmacokinetics; ultraviolet detection; chitosan; mucoadhesive; polymeric nanoparticles; sustained release; oral drug delivery; glucuronidation; obesity; sex; polymorphisms; n/a; bioavailability; bioequivalence; intramuscular; auto-injector; sublingual delivery; rapidly-disintegrating; tablets; allergy; anaphylaxis; adrenaline; epinephrine; creatine monohydrate; pharmacokinetics; oral bioavailability; LC-MS/MS; physiology-based pharmacokinetic modeling